Tag: acorda therapeutics
December 24, 2018
Pharma Outlook 2019: Drug Pricing Dialogue Continues
During this challenging time in healthcare news, our pharma outlook aims to help investors steer through the industry. October 31, 2018
Acorda Provides Financial and Pipeline Update for Third Quarter 2018
Acorda Therapeutics (Nasdaq:ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2018. As quoted in... January 30, 2017
Biotech Executives on Trump’s Immigration Ban
Donald Trump's immigration ban has sparked outrage around the world, and biotech executives are speaking out. November 24, 2016
What Will Trump's Presidency Mean for Pharma Stocks?
With January fast approaching, it’s worthwhile to reexamine Trump’s stance on various industry-related questions. November 21, 2016
Acorda Discontinues Dalfampridine for Treatment of Post-Stroke Mobility Issues
Acorda Therapeutics has announced that results from its MILESTONE clinical study did not support continued development of dalfampridine as a... June 13, 2016
Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective
TURKU, Finland–(BUSINESS WIRE)–Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) (“Biotie” or the “Company”) announces that the voluntary delisting of its American... May 18, 2016